Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Genomic Health Inc (GHDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Here's Why You Should Invest in Genomic Health (GHDX) Now

Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.

HOLX : 46.79 (-0.13%)
ITGR : 82.37 (-2.09%)
GHDX : 70.70 (+1.92%)
VEEV : 123.50 (+0.31%)
New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test

Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna reinforce the utility of the Oncotype DX Breast Recurrence...

GHDX : 70.70 (+1.92%)
Report: Exploring Fundamental Drivers Behind ON Semiconductor, Pilgrim's Pride, Merck & Co., Healthcare Services Group, Genomic Health, and Spectrum Pharmaceuticals -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ON Semiconductor Corporation...

SPPI : 9.80 (+2.40%)
PPC : 21.69 (+1.12%)
GHDX : 70.70 (+1.92%)
MRK : 82.43 (+0.17%)
HCSG : 32.50 (+1.12%)
ON : 20.99 (-3.00%)
New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score® Test to Target Chemotherapy

- Real-world evidence reinforces TAILORx treatment paradigm and standard of care use for Oncotype DX((R)) test

GHDX : 70.70 (+1.92%)
Why Is Genomic Health (GHDX) Down 4.8% Since Last Earnings Report?

Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GHDX : 70.70 (+1.92%)
Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up

Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.

CELG : 87.98 (-0.19%)
GHDX : 70.70 (+1.92%)
JNJ : 136.54 (-0.27%)
GERN : 1.63 (-3.55%)
After Yesterday's Decline of 1.99%, Genomic Health I Offers Investors Better Value

Genomic Health I (NASDAQ:GHDX) traded in a range yesterday that spanned from a low of $74.01 to a high of $76.76. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of...

GHDX : 70.70 (+1.92%)
Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4

Esperion Therapeutics (ESPR) generates no revenues in the fourth quarter. The company provides guidance for 2019.

ESPR : 41.37 (-0.05%)
CELG : 87.98 (-0.19%)
GHDX : 70.70 (+1.92%)
MRK : 82.43 (+0.17%)
Spectrum (SPPI) Misses Earnings Estimates in Q4, Tops Sales

Spectrum Pharma (SPPI) misses bottom-line estimates in the fourth quarter but beats on revenues.

SPPI : 9.80 (+2.40%)
CELG : 87.98 (-0.19%)
GHDX : 70.70 (+1.92%)
AMGN : 186.51 (-0.10%)
Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up

Sarepta (SRPT) misses estimates for both earnings and sales in fourth-quarter 2018. However, Exondys 51 performs well on strong demand.

CELG : 87.98 (-0.19%)
GHDX : 70.70 (+1.92%)
SRPT : 119.02 (-2.65%)
BMRN : 88.50 (+0.51%)
Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues

Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.

CELG : 87.98 (-0.19%)
GHDX : 70.70 (+1.92%)
ARNA : 44.04 (+1.87%)
UTHR : 120.13 (-0.55%)
Earnings Estimates Rising for Genomic Health (GHDX): Will It Gain?

Genomic Health (GHDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

GHDX : 70.70 (+1.92%)
Genomic Health I Set to Possibly Rebound After Yesterday's Selloff of 5.79%

Genomic Health I (NASDAQ:GHDX) traded in a range yesterday that spanned from a low of $75.37 to a high of $86.60. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of...

GHDX : 70.70 (+1.92%)
Diagnostic Solutions Laboratory Revolutionizes Precision Medicine with GenomicInsight(TM) Genomic Health Profile Powered by Opus23 Explorer(TM)

Diagnostic Solutions Laboratory (DSL) continues its innovative vision to transform and improve personalized medicine by introducing its first DNA SNP test, GenomicInsight(TM) Genomic Health Profile powered...

GHDX : 70.70 (+1.92%)
Genomic Health (GHDX) Beats Q4 Earnings and Revenue Estimates

Genomic Health (GHDX) delivered earnings and revenue surprises of 6.67% and 2.73%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

GHDX : 70.70 (+1.92%)
Genomic Health: 4Q Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Genomic Health Inc. (GHDX) on Wednesday reported fourth-quarter net income of $8.9 million.

GHDX : 70.70 (+1.92%)
Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance

Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2018.

GHDX : 70.70 (+1.92%)
Global Liquid Biopsy Market to 2024 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad Labs, Biocept, Biocartis, Myriad Genetics, Genomic Health, NeoGenomics Laboratories, & Qiagen

The "Liquid Biopsy Market, Global Analysis by Cancer, Product, Circulating Biomarkers, Clinical Application, Regions, and Companies" report has been added to ResearchAndMarkets.com's offering.

GHDX : 70.70 (+1.92%)
MYGN : 33.15 (+0.15%)
What's in the Cards for Genomic Health (GHDX) in Q4 Earnings?

Genomic Health (GHDX) is expected to gain from higher Oncotype DX breast cancer test revenues in Q4.

WMGI : 31.73 (+0.35%)
CVS : 54.88 (-2.07%)
GHDX : 70.70 (+1.92%)
MASI : 134.61 (+0.70%)
Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019

Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end...

GHDX : 70.70 (+1.92%)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ +0.08
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar